HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
23 hedge funds and large institutions have $9.07M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 0 closing their positions.
10% more funds holding
Funds holding: 21 → 23 (+2)
10% less capital invested
Capital invested by funds: $10M → $9.07M (-$984K)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$79.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$75.6K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$50.8K |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.6K |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$1.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$310K |
| 2 |
BG
BlackRock Group
London,
United Kingdom
|
-$115K |
| 3 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
-$32K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$26.9K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$9.14K |
HTGM Hedge Fund Activity: Q2 2016 in Review
23 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q2 2016, worth a combined $9.07M — down 9.8% from $10M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new HTGM positions and 0 closed out — a net gain of 2 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $79.2K. The largest seller was BlackRock Advisors, cutting an estimated $310K.
- 23 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q2 2016, up from 21 in Q1 2016.
- Funds reported $9.07M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q2 2016, down 9.8% quarter-over-quarter.
- 2 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q2 2016 and 0 closed out, a net change of +2 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q2 2016 was Renaissance Technologies, an estimated $79.2K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q2 2016 was BlackRock Advisors, an estimated $310K sold.
Based on aggregated 13F filings for Q2 2016.